CAMBRIDGE, Mass. and ZUG,
Switzerland, June 7, 2021 /PRNewswire/ -- Moderna,
Inc. (Nasdaq: MRNA), a biotechnology company pioneering
messenger RNA (mRNA) therapeutics and vaccines and Medison Pharma,
a leading commercial partner for highly innovative therapies in
international markets, today announced a new agreement to
commercialize the Moderna COVID-19 Vaccine across Central
Eastern Europe and Israel.
The agreement covers the following countries: Poland, Czech
Republic, Romania,
Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia and
Herzegovina, Kosovo,
North Macedonia, Montenegro, and Israel.
"We are excited to partner with Moderna in 20 markets, covering
over 175 million lives across the entire Central Eastern Europe
region and in Israel," said Meir
Jakobsohn, Founder and CEO of Medison Pharma. "Moderna's
breakthrough mRNA vaccine and Medison's international
commercialization platform for highly innovative treatments, makes
our partnership a natural fit."
"We appreciate this new partnership with Medison Pharma to
ensure successful delivery of our mRNA COVID-19 vaccine to market,"
said Corinne Le Goff, Pharm.D.,
M.B.A., Chief Commercial Officer of Moderna. "Working together with
our partners, we remain steadfast in our commitment to fighting the
pandemic by delivering our vaccine to populations
globally."
About Medison Pharma
Medison is a global pharma company focusing on commercializing
highly innovative therapies for patients in international
markets.
Leveraging a track record of over 25 years and partnerships with
leading biotech companies, Medison provides a complete spectrum of
integrated services for companies interested in establishing
presence in international markets.
Medison also runs a corporate venture arm with a dedicated
research and evaluation team boasting deep scientific and
commercial expertise.
For more information, visit https://www.medison.co.il/.
About Moderna
In 10 years since its inception, Moderna has
transformed from a science research-stage company advancing
programs in the field of messenger RNA (mRNA), to an enterprise
with a diverse clinical portfolio of vaccines and therapeutics
across six modalities, a broad intellectual property portfolio in
areas including mRNA and lipid nanoparticle formulation, and an
integrated manufacturing plant that allows for both clinical and
commercial production at scale and at unprecedented
speed. Moderna maintains alliances with a broad range of
domestic and overseas government and commercial collaborators,
which has allowed for the pursuit of both groundbreaking science
and rapid scaling of manufacturing. Most recently, Moderna's
capabilities have come together to allow the authorized use of one
of the earliest and most-effective vaccines against the COVID-19
pandemic.
Moderna's mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Today, 24 development programs
are underway across these therapeutic areas, with 13 programs
having entered the clinic. Moderna has been named a top
biopharmaceutical employer by Science for the past
six years. To learn more, visit www.modernatx.com.
Moderna Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding an agreement between Moderna
and Medison Pharma to commercialize the Moderna COVID-19 Vaccine
(known as COVID-19 Vaccine Moderna outside the U.S.) in Central
Eastern Europe and Israel. In some
cases, forward-looking statements can be identified by terminology
such as "will," "may," "should," "could", "expects," "intends,"
"plans," "aims," "anticipates," "believes," "estimates,"
"predicts," "potential," "continue," or the negative of these terms
or other comparable terminology, although not all forward-looking
statements contain these words. The forward-looking statements in
this press release are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond Moderna's control and which
could cause actual results to differ materially from those
expressed or implied by these forward-looking statements. These
risks, uncertainties, and other factors include, among others: the
fact that there has never been a commercial product utilizing mRNA
technology approved for use; the fact that the rapid response
technology in use by Moderna is still being developed and
implemented; the safety, tolerability and efficacy profile of the
Moderna COVID-19 Vaccine observed to date may change adversely in
ongoing analyses of trial data or subsequent to commercialization;
despite having ongoing interactions with the FDA or other
regulatory agencies, the FDA or such other regulatory agencies may
not agree with Moderna's regulatory approval strategies, components
of our filings, such as clinical trial designs, conduct and
methodologies, or the sufficiency of data submitted; Moderna may
encounter delays in meeting manufacturing or supply timelines or
disruptions in its distribution plans for the Moderna COVID-19
Vaccine; whether and when any biologics license applications and/or
emergency use authorization applications may be filed and
ultimately approved by regulatory authorities; potential adverse
impacts due to the global COVID-19 pandemic such as delays in
regulatory review, manufacturing and clinical trials, supply chain
interruptions, adverse effects on healthcare systems and disruption
of the global economy; and those other risks and uncertainties
described under the heading "Risk Factors" in Moderna's most recent
Annual Report on Form 10-K filed with the U.S. Securities and
Exchange Commission (SEC) and in subsequent filings made by Moderna
with the SEC, which are available on the SEC's website at
www.sec.gov. Except as required by law, Moderna disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on Moderna's current
expectations and speak only as of the date hereof.
Logo -
https://mma.prnewswire.com/media/1327958/Medison_Pharma_Logo.jpg
For more information, please contact:
Moderna Contacts
Media:
Colleen Hussey
Director, Corporate Communications
617-335-1374
Colleen.Hussey@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com
Medison Contact
Maya Nix
Corporate Communications Lead
mayan@medison.co.il
+972-3-925-0260